Cargando…
Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen. Understanding the magnitude and duration of protective immune responses is vital to curbing the pandemic. We enrolled 461 high-risk health se...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575273/ https://www.ncbi.nlm.nih.gov/pubmed/34748607 http://dx.doi.org/10.1371/journal.pone.0259703 |
_version_ | 1784595644714844160 |
---|---|
author | Gray, Ashley N. Martin-Blais, Rachel Tobin, Nicole H. Wang, Yan Brooker, Sarah L. Li, Fan Gadoth, Adva Elliott, Julie Faure-Kumar, Emmanuelle Halbrook, Megan Hofmann, Christian Kashani, Saman Kazan, Clayton Yang, Otto O. Fulcher, Jennifer A. Grovit-Ferbas, Kathie Rimoin, Anne W. Aldrovandi, Grace M. |
author_facet | Gray, Ashley N. Martin-Blais, Rachel Tobin, Nicole H. Wang, Yan Brooker, Sarah L. Li, Fan Gadoth, Adva Elliott, Julie Faure-Kumar, Emmanuelle Halbrook, Megan Hofmann, Christian Kashani, Saman Kazan, Clayton Yang, Otto O. Fulcher, Jennifer A. Grovit-Ferbas, Kathie Rimoin, Anne W. Aldrovandi, Grace M. |
author_sort | Gray, Ashley N. |
collection | PubMed |
description | Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen. Understanding the magnitude and duration of protective immune responses is vital to curbing the pandemic. We enrolled 461 high-risk health services workers at the University of California, Los Angeles (UCLA) and first responders in the Los Angeles County Fire Department (LACoFD) to assess the humoral responses in previously infected (PI) and infection naïve (NPI) individuals to mRNA-based vaccines (BNT162b2/Pfizer- BioNTech or mRNA-1273/Moderna). A chemiluminescent microparticle immunoassay was used to detect antibodies against SARS-CoV-2 Spike in vaccinees prior to (n = 21) and following each vaccine dose (n = 246 following dose 1 and n = 315 following dose 2), and at days 31–60 (n = 110) and 61–90 (n = 190) following completion of the 2-dose series. Both vaccines induced robust antibody responses in all immunocompetent individuals. Previously infected individuals achieved higher median peak titers (p = 0.002) and had a slower rate of decay (p = 0.047) than infection-naïve individuals. mRNA-1273 vaccinated infection-naïve individuals demonstrated modestly higher titers following each dose (p = 0.005 and p = 0.029, respectively) and slower rates of antibody decay (p = 0.003) than those who received BNT162b2. A subset of previously infected individuals (25%) required both doses in order to reach peak antibody titers. The biologic significance of the differences between previously infected individuals and between the mRNA-1273 and BNT162b2 vaccines remains uncertain, but may have important implications for booster strategies. |
format | Online Article Text |
id | pubmed-8575273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-85752732021-11-09 Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection Gray, Ashley N. Martin-Blais, Rachel Tobin, Nicole H. Wang, Yan Brooker, Sarah L. Li, Fan Gadoth, Adva Elliott, Julie Faure-Kumar, Emmanuelle Halbrook, Megan Hofmann, Christian Kashani, Saman Kazan, Clayton Yang, Otto O. Fulcher, Jennifer A. Grovit-Ferbas, Kathie Rimoin, Anne W. Aldrovandi, Grace M. PLoS One Research Article Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen. Understanding the magnitude and duration of protective immune responses is vital to curbing the pandemic. We enrolled 461 high-risk health services workers at the University of California, Los Angeles (UCLA) and first responders in the Los Angeles County Fire Department (LACoFD) to assess the humoral responses in previously infected (PI) and infection naïve (NPI) individuals to mRNA-based vaccines (BNT162b2/Pfizer- BioNTech or mRNA-1273/Moderna). A chemiluminescent microparticle immunoassay was used to detect antibodies against SARS-CoV-2 Spike in vaccinees prior to (n = 21) and following each vaccine dose (n = 246 following dose 1 and n = 315 following dose 2), and at days 31–60 (n = 110) and 61–90 (n = 190) following completion of the 2-dose series. Both vaccines induced robust antibody responses in all immunocompetent individuals. Previously infected individuals achieved higher median peak titers (p = 0.002) and had a slower rate of decay (p = 0.047) than infection-naïve individuals. mRNA-1273 vaccinated infection-naïve individuals demonstrated modestly higher titers following each dose (p = 0.005 and p = 0.029, respectively) and slower rates of antibody decay (p = 0.003) than those who received BNT162b2. A subset of previously infected individuals (25%) required both doses in order to reach peak antibody titers. The biologic significance of the differences between previously infected individuals and between the mRNA-1273 and BNT162b2 vaccines remains uncertain, but may have important implications for booster strategies. Public Library of Science 2021-11-08 /pmc/articles/PMC8575273/ /pubmed/34748607 http://dx.doi.org/10.1371/journal.pone.0259703 Text en © 2021 Gray et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Gray, Ashley N. Martin-Blais, Rachel Tobin, Nicole H. Wang, Yan Brooker, Sarah L. Li, Fan Gadoth, Adva Elliott, Julie Faure-Kumar, Emmanuelle Halbrook, Megan Hofmann, Christian Kashani, Saman Kazan, Clayton Yang, Otto O. Fulcher, Jennifer A. Grovit-Ferbas, Kathie Rimoin, Anne W. Aldrovandi, Grace M. Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection |
title | Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection |
title_full | Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection |
title_fullStr | Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection |
title_full_unstemmed | Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection |
title_short | Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection |
title_sort | humoral responses to sars-cov-2 mrna vaccines: role of past infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575273/ https://www.ncbi.nlm.nih.gov/pubmed/34748607 http://dx.doi.org/10.1371/journal.pone.0259703 |
work_keys_str_mv | AT grayashleyn humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT martinblaisrachel humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT tobinnicoleh humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT wangyan humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT brookersarahl humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT lifan humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT gadothadva humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT elliottjulie humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT faurekumaremmanuelle humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT halbrookmegan humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT hofmannchristian humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT kashanisaman humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT kazanclayton humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT yangottoo humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT fulcherjennifera humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT grovitferbaskathie humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT rimoinannew humoralresponsestosarscov2mrnavaccinesroleofpastinfection AT aldrovandigracem humoralresponsestosarscov2mrnavaccinesroleofpastinfection |